CA3169407A1 - Compositions and methods for treating and preventing hepatitis b and d - Google Patents
Compositions and methods for treating and preventing hepatitis b and dInfo
- Publication number
- CA3169407A1 CA3169407A1 CA3169407A CA3169407A CA3169407A1 CA 3169407 A1 CA3169407 A1 CA 3169407A1 CA 3169407 A CA3169407 A CA 3169407A CA 3169407 A CA3169407 A CA 3169407A CA 3169407 A1 CA3169407 A1 CA 3169407A1
- Authority
- CA
- Canada
- Prior art keywords
- nucleic acid
- hepatitis
- seq
- immunogenic composition
- product combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10111—Deltavirus, e.g. hepatitis delta virus
- C12N2760/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Beans For Foods Or Fodder (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062966970P | 2020-01-28 | 2020-01-28 | |
| US62/966,970 | 2020-01-28 | ||
| PCT/US2021/015126 WO2021154752A1 (en) | 2020-01-28 | 2021-01-26 | Compositions and methods for treating and preventing hepatitis b and d |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3169407A1 true CA3169407A1 (en) | 2021-08-05 |
Family
ID=74673345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3169407A Pending CA3169407A1 (en) | 2020-01-28 | 2021-01-26 | Compositions and methods for treating and preventing hepatitis b and d |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230079898A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4096711A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7855515B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220149519A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115335075A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021214939A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3169407A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022009169A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021154752A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101564533B (zh) * | 2009-06-12 | 2012-01-04 | 东南大学 | 戊型肝炎蛋白-核酸复合疫苗及其制备方法 |
| CN102895659B (zh) * | 2011-07-29 | 2014-10-29 | 复旦大学 | 一种防治老年痴呆症复合疫苗及其制备方法 |
| US10905760B2 (en) | 2016-01-28 | 2021-02-02 | Svenska Vaccinfabriken Produktion Ab | Chimeric hepatitis D virus antigen and hepatitis B virus pre S1 genes for use alone or in vaccines containing hepatitis B virus genes |
| AU2017332854B2 (en) * | 2016-09-21 | 2024-11-14 | The Governors Of The University Of Alberta | Hepatitis C virus immunogenic compositions and methods of use thereof |
-
2021
- 2021-01-26 CN CN202180022581.7A patent/CN115335075A/zh active Pending
- 2021-01-26 WO PCT/US2021/015126 patent/WO2021154752A1/en not_active Ceased
- 2021-01-26 US US17/794,786 patent/US20230079898A1/en not_active Abandoned
- 2021-01-26 EP EP21707475.6A patent/EP4096711A1/en active Pending
- 2021-01-26 AU AU2021214939A patent/AU2021214939A1/en active Pending
- 2021-01-26 MX MX2022009169A patent/MX2022009169A/es unknown
- 2021-01-26 JP JP2022546448A patent/JP7855515B2/ja active Active
- 2021-01-26 CA CA3169407A patent/CA3169407A1/en active Pending
- 2021-01-26 KR KR1020227029043A patent/KR20220149519A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7855515B2 (ja) | 2026-05-08 |
| AU2021214939A1 (en) | 2022-09-15 |
| KR20220149519A (ko) | 2022-11-08 |
| CN115335075A (zh) | 2022-11-11 |
| JP2023512526A (ja) | 2023-03-27 |
| EP4096711A1 (en) | 2022-12-07 |
| US20230079898A1 (en) | 2023-03-16 |
| WO2021154752A1 (en) | 2021-08-05 |
| MX2022009169A (es) | 2022-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11478544B2 (en) | Chimeric hepatitis D virus antigen and hepatitis B virus pre S1 genes for use alone or in vaccines contaning hepatitis B virus genes | |
| EP2391383B1 (en) | Codon-optimized hepatitis b virus core antigen (hbcag) | |
| CA3176902A1 (en) | Compositions and methods for treating and preventing coronaviruses | |
| JP6259831B2 (ja) | C型肝炎ウイルスに対するキメラワクチン抗原 | |
| CN109422816B (zh) | 一种靶向次级淋巴组织的肝癌疫苗 | |
| US20160324954A1 (en) | Immunogenic compositions for inhibiting hepatitis d virus | |
| US20250197452A1 (en) | Compositions and methods for treating and preventing hepatitis b and d | |
| US20230079898A1 (en) | Compositions and methods for treating and preventing hepatitis b and d | |
| RU2812764C1 (ru) | Композиции и способы для лечения и предотвращения гепатита в и d | |
| HK40083708A (en) | Compositions and methods for treating and preventing hepatitis b and d | |
| US20240382584A1 (en) | Hbv vaccine inducing pres-specific neutralizing antibodies | |
| CN119113097A (zh) | 用于治疗乙型肝炎感染的方法和组合物 | |
| AU2004281098B2 (en) | Pharmaceutical compositions for therapeutic use | |
| EP4676527A2 (en) | Compositions and methods for treating and preventing crimean congo hemorrhagic fever virus | |
| GB2440528A (en) | Antigen-antibody complexes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220928 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20240702 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20240926 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250108 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250108 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250108 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250110 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250110 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250605 |
|
| T11 | Administrative time limit extension requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-T10-T11-T100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTENSION OF TIME FOR TAKING ACTION REQUEST RECEIVED Effective date: 20251002 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20251120 |
|
| T13 | Administrative time limit extension granted |
Free format text: ST27 STATUS EVENT CODE: A-2-2-T10-T13-T101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTENSION OF TIME FOR TAKING ACTION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251211 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251211 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251230 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251230 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260106 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260106 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260106 |